BPC-157

What is BPC-157?#

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It consists of 15 amino acids and has been extensively studied in preclinical models for its tissue-protective and healing properties.

Mechanism of Action#

Mechanistic overview BPC‑157 is a 15–amino‑acid gastric peptide with pleiotropic, predominantly endothelial/cytoprotective actions. Across models, its effects converge on angiogenic and nitric oxide (NO) signaling, cytoskeletal/migratory programs, and barrier stabilization, rather than a single canonical receptor. A broad receptor binding screen reported no direct pharmacological affinity for the classical neurotransmitter receptor families tested, supporting an indirect or upstream modulatory mode of action.

Primary signaling pathways and molecular targets

1. VEGF–VEGFR2–Akt–eNOS axis

• VEGF/VEGFR regulation: BPC‑157 upregulates VEGF‑A and VEGFR1/VEGFR2, and rapidly induces VEGFR2 phosphorylation with receptor internalization; the endocytosis inhibitor dynasore blocks these effects, indicating a requirement for VEGFR2 internalization.
• Downstream effectors: Activated VEGFR2 leads to AKT phosphorylation and eNOS activation; BPC‑157 decreases eNOS–Caveolin‑1 binding (releasing eNOS), consistent with increased NO bioactivity.
• Context dependence: In clopidogrel‑impaired angiogenesis, BPC‑157 increased VEGF‑A/VEGFR1 and AKT phosphorylation while inactivating p38/ERK MAPKs; NOS inhibition (L‑NAME) abrogated AKT and p38 effects but not ERK, indicating partial NO‑dependence.

2. Src–Caveolin‑1–eNOS vasomotor signaling

• BPC‑157 engages Src–Caveolin‑1–eNOS signaling to modulate vasomotor tone and collateral recruitment, aligning with rapid endothelial protection and bypass of occlusions; this includes decreased eNOS/Caveolin‑1 interaction and increased eNOS activity.

3. NO‑system modulation and antioxidant effects

• Bidirectional normalization: BPC‑157 counteracts both NOS inhibition (e.g., L‑NAME) and NOS overstimulation (e.g., L‑arginine), normalizing tissue NO levels while suppressing free radical formation across ischemia/reperfusion and other injury models.
• Functional outcomes: Effects include protection from thrombosis/arrhythmias and improved perfusion linked to collateral vessel recruitment.

4. MAPK and immediate‑early transcriptional responses

• MAPK modulation: Context‑dependent effects on MAPK signaling are reported—BPC‑157 can inactivate p38/ERK in certain impaired‑angiogenesis contexts, yet also rapidly activates ERK1/2 with induction of egr‑1 and its repressor nab2, and modulates c‑Fos/c‑Jun during endothelial proliferation and wound repair.

5. Cell migration and adhesion: FAK–paxillin

• BPC‑157 activates focal adhesion kinase (FAK) and paxillin, promoting fibroblast outgrowth and migration, consistent with enhanced repair programs in tendon and endothelial cells.

6. Growth hormone receptor (GHR) and JAK‑STAT facilitation

• Direct receptor expression change: In tendon fibroblasts, BPC‑157 upregulates GHR mRNA/protein and potentiates GH‑induced JAK2 phosphorylation, increasing proliferation—an example of target‑cell receptor sensitization rather than direct GH‑receptor agonism.

7. Platelet/thrombocyte function without coagulation cascade alteration

• BPC‑157 improves thrombocyte function and reduces bleeding or thrombosis manifestations in vivo while standard coagulation parameters remain unaffected, implying modulation of platelet activation/adhesion or endothelial–platelet interactions.

8. Barrier/cytoprotection and vascular remodeling

• Endothelial/epithelial stabilization: Reports describe stabilization of cellular junctions and membrane protective effects, aligning with decreased permeability and “leaky‑gut” correction; rapid activation of collateral circulation (e.g., azygos flow) to bypass occlusions is consistently noted.

Receptor interactions

• Classical receptor binding: No demonstrable affinity for standard neurotransmitter receptor families in an expanded receptor screen.
• Growth factor receptors: Functional activation/upregulation of VEGFR2 (with internalization‑dependent signaling) is repeatedly implicated; GH receptor expression is increased in fibroblasts, enhancing responsiveness to endogenous GH.
• Neurotransmitter systems: Although behavioral/physiological data indicate normalization across dopaminergic, serotonergic, glutamatergic, GABAergic, cholinergic, and adrenergic systems, the absence of direct binding suggests upstream vascular/cytoprotective and NO‑related mechanisms mediating these effects.

Integrated mechanism of action BPC‑157 acts as a cytoprotective, pro‑reparative modulator centered on the endothelial VEGFR2→AKT→eNOS axis and Src–Caveolin‑1–eNOS signaling, normalizing NO bioavailability and redox balance, while engaging FAK–paxillin migration programs and selectively increasing target‑cell receptor responsiveness (e.g., GHR). These convergent actions stabilize vascular and epithelial barriers, promote angiogenesis and collateral circulation, and secondarily harmonize neural and hemostatic disturbances—without evidence of direct agonism at classical neurotransmitter receptors.

Key mechanistic map

Limitations Much of the mechanistic evidence is preclinical and concentrated in a limited investigator network; comprehensive receptor deconvolution and unbiased target identification remain incomplete, and direct binding to a primary receptor has not been established.

Therapeutic Applications#

Gastrointestinal ischemia/colitis and reperfusion. In rat colonic ischemia–reperfusion, topical BPC‑157 (10 µg/kg bath) rapidly restored microvascular perfusion: the ischemic pale area declined from 86 ± 8% with saline to 10 ± 2% within 15 min, with normalization of tissue malondialdehyde and NO levels and preservation of mucosal folds; effects persisted in obstructed segments and during reperfusion (vs NOS modulators).

External/internal fistula healing. In a rat colocutaneous fistula model, daily BPC‑157 (10 µg/kg ip or oral 0.16 µg/mL; also 10 ng/kg) achieved early improvement and complete fistula closure by day 28; BPC‑157 outperformed sulphasalazine and corticosteroid aggravated healing (functional water-holding improved; colon and skin defects closed). In rat rectovaginal fistula, BPC‑157 (ip or oral, µg/ng regimens) led to no fecal leakage in all treated rats versus persistent leakage in controls, complete epithelialization by ~day 14, and robust neovascularization (>10 new vessels/HPF by week 3); controls showed ongoing defects, adhesions, and obstruction.

Intestinal anastomosis and vascular recruitment. Across rat anastomosis/ischemia models, BPC‑157 accelerated revascularization, recruited collaterals, preserved mucosa, and reduced adhesions, consistent with its NO/angiogenesis modulation; quantitative perfusion and lesion-size data above support these effects.

Tendon and ligament healing. After rat medial collateral ligament transection, BPC‑157 given ip, orally, or locally restored biomechanical properties toward normal by day 14: breaking force ~34.1 ± 5.2 N, elongation ~2.3 ± 0.2 mm, absorbed energy ~34.8 ± 4.8 N·mm, stiffness ~20.3 ± 3.2 N/mm; macroscopic fiber organization normalized and inflammatory markers decreased. In vitro, BPC‑157 increased tendon fibroblast growth‑hormone receptor expression, supporting enhanced tendon cell proliferation when combined with GH.

Spinal cord injury and neuroprotection. In rat sacrocaudal spinal cord compression, a single ip dose of BPC‑157 (2 or 200 µg/kg) 10 min post‑injury produced consistent functional recovery: improved tail motor scores, spasticity resolved by day ~15, and autotomy avoided; histology showed markedly fewer vacuoles/necrosis in white and gray matter (significant vs controls); EMG showed lower motor‑unit potentials (indicating preserved motoneurons) without demyelination on conduction studies.

Ocular (glaucoma model). In rat open‑angle glaucoma induced by cauterizing three episcleral veins, BPC‑157 given as eye drops (0.4 µg/eye or 0.4 ng/eye), ip, or orally immediately normalized intraocular pressure, reversed mydriasis, and preserved retinal ganglion cells, optic nerve thickness, and fundus/retinal/choroidal vessel appearance; benefits were seen both prophylactically and when started 24 h post‑injury.

Skin/burn wound healing and angiogenesis. In a rat alkali‑burn model, topical BPC‑157 (200–800 ng/mL) accelerated closure to ~77–82% by day 18 vs 60.0 ± 9.8% in controls and matched or approached bFGF; histology showed superior granulation, re‑epithelialization, collagen deposition, and increased VEGF‑A; in HUVECs, BPC‑157 increased proliferation, migration, and tube formation via ERK1/2 signaling.

Stress urinary incontinence (SUI). In female rat SUI models (transabdominal urethrolysis and prolonged vaginal dilatation), BPC‑157 (ip 10 µg/kg or 10 ng/kg daily, or oral 10 µg/kg) restored leak‑point pressure to near‑healthy values across regimens; histology showed higher desmin and SMA positivity and increased CD34+ vessel density with preserved muscle/connective tissue ratios.

Analgesia. In rat incisional and formalin pain paradigms, BPC‑157 produced short‑lived antinociception: increased mechanical thresholds at 2 h and improved thresholds at day 4 in incisional pain; reduced phase‑1 flinches in the formalin test without effect in phase‑2 and with shorter duration than morphine.

Clinical research and safety notes. A registered Phase 1 safety/pharmacokinetics study (PCO‑02; NCT02637284) exists, with status unclear in our snapshot. Narrative clinical summaries report a multicenter randomized double‑blind placebo‑controlled enema trial (n≈53) in mild–moderate ulcerative colitis showing statistically significant decreases in Disease Activity Index, improved stool metrics, and histology versus placebo, and a single‑blind healthy‑volunteer enema dose‑escalation study showing good tolerability and minimal systemic absorption; however, primary registry outcome details were not obtained here. Overall, human efficacy data remain sparse and preliminary relative to extensive rodent evidence.

Key takeaways

• Across multiple rat models, BPC‑157 consistently improved tissue perfusion, reduced ischemic injury, and accelerated healing of fistulas, anastomoses, tendons/ligaments/muscle, spinal cord, ocular tissues, and skin, often with quantitative improvements versus saline and, in some cases, outperforming standard comparators (e.g., sulphasalazine).
• Mechanistic correlates include modulation of NO/VEGFR2–Akt–eNOS and ERK1/2 pathways, angiogenesis, and endothelial protection demonstrated in several models, with functional and histologic endpoints aligning.
• Human clinical evidence is limited to early‑phase and small trials with reported safety and signals in ulcerative colitis; robust randomized clinical efficacy across indications is lacking in accessible datasets here.

Embedded summary table

Limitations Most preclinical studies are from a small number of groups, often in rodents, and some journals are lower tier; replication in independent labs and larger animal models is limited. Human trials are few; thus, while therapeutic applications appear broad in animals, translation to clinical practice remains unproven pending rigorous randomized studies.

Preclinical Evidence#

Scope and overall quality of the evidence base The scientific literature for BPC‑157 (also known as PL‑14736) is dominated by preclinical animal studies and narrative reviews authored by overlapping research groups. Reviews report pleiotropic effects across gastrointestinal, musculoskeletal, vascular, and central nervous system models, often attributing benefits to modulation of angiogenesis and the nitric oxide (NO) system. However, independent replication is limited, methodological detail is variable, and many publications appear in lower‑quality venues. Human evidence remains sparse, with few small early‑phase studies and limited or absent registry‑posted outcomes, which constrains confidence in clinical efficacy claims.

Human studies and clinical trial registry landscape

• Phase 1 oral safety/PK (PCO‑02): A ClinicalTrials.gov record exists (NCT02637284) for a Phase 1 safety and pharmacokinetics study in 42 healthy volunteers. Reviews report oral self‑administration at 1–9 mg/day for up to two weeks, “safe and well tolerated,” but with no quantifiable BPC‑157 detected in plasma or urine; no posted results were identified in retrieved sources.
• Phase I rectal PK in healthy men: A single‑blind, placebo‑controlled rectal dosing study (2001 FOCUS report) in 32 healthy males reportedly found good tolerability with most plasma concentrations below the assay’s lower limit of quantification (LLQ), indicating uncertain systemic exposure with this route.
• Ulcerative colitis RCT: A review describes a multicenter, randomized, double‑blind, placebo‑controlled trial in 53 patients with mild–moderate ulcerative colitis using an 80 mg enema daily for two weeks, reporting a significant decrease in Disease Activity Index and favorable tolerability; no registry identifier or posted full results were found in the retrieved sources, and details remain limited.
• Small uncontrolled/retrospective series: Reviews cite private‑clinic series (e.g., intra‑articular injections for knee pain, n=16; interstitial cystitis, n=12) reporting high response rates but lacking controls, with potential reporting bias and unclear publication status. Collectively, the identifiable registry footprint appears to be limited to NCT02637284, while other claimed human studies are not readily verifiable in public registries based on retrieved data.

Pharmacokinetics, mechanism, and safety signals Across human Phase 1 contexts, plasma levels are frequently below quantification limits, raising uncertainty about systemic exposure following oral or rectal dosing as studied. Proposed mechanisms center on angiogenesis modulation and NO‑system interactions, but remain incompletely defined in humans. Animal toxicology summaries claim high acute tolerability (e.g., LD50 not reached at high doses); human safety assertions rely on small early‑phase studies and anecdotal/compounding reports without systematic pharmacovigilance.

Regulatory and anti‑doping status Reviews and brief reports indicate no marketing approval by the U.S. FDA identified in the retrieved sources. With respect to anti‑doping rules, prior literature noted BPC‑157 was “not currently on the WADA list” at earlier time points; other sources describe temporary attention or prohibition in recent years, but retrieved texts do not provide definitive, citable WADA listing timelines. Overall, regulatory approval is lacking in the sources consulted, and anti‑doping positions appear to have been evolving, with ambiguity remaining in the retrieved evidence.

Key limitations, evidence gaps, and criticisms

• Scarcity of rigorous human trials: Only one identifiable registered Phase 1 oral study (NCT02637284) and no conclusively verifiable, registry‑posted efficacy trials in the sources retrieved; a reported 53‑patient ulcerative colitis RCT lacks a registry ID and full public results.
• Uncertain pharmacokinetics/systemic exposure: Human studies frequently report plasma levels below LLQ after oral/rectal dosing; assay sensitivity and bioavailability remain unclear.
• Concentration of authorship and limited independent replication: Many preclinical findings originate from overlapping groups; broader, independent replication is limited.
• Methodological and reporting issues: Variable detail in preclinical methods, small sample sizes, inconsistent endpoints, and lack of adverse‑event reporting are common critiques.
• Publication venue concerns: Several comprehensive reviews and many primary reports appear in lower‑quality journals, which may weaken confidence in peer‑review rigor.
• Regulatory/anti‑doping ambiguity: No FDA approval is evident in retrieved sources; WADA status has been variably described historically, and definitive, citable rulings or timelines were not identified in the retrieved texts.

Practical conclusion The evidence base for BPC‑157 is broad in preclinical scope but narrow in high‑quality human data. Human clinical efficacy remains unconfirmed by robust, publicly posted randomized trials, and pharmacokinetics after common administration routes are uncertain. Concerns about replication, methodological rigor, and publication venues temper confidence. Absent clear regulatory approvals and with evolving anti‑doping considerations, BPC‑157 should be regarded as investigational, with substantial evidence gaps that warrant well‑designed, independently led clinical trials with transparent registration and reporting.

Evidence Gaps and Limitations#

The current evidence base for BPC-157 consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in human tendon fibroblasts, published in Molecules (Chang CH et al., 2014; PMID: 25415472):

This study examined BPC-157's effects on growth hormone receptor expression in human tendon cells, suggesting a potential mechanism for its tissue healing properties.

• Increased GH receptor expression in tendon fibroblasts
• Enhanced cell migration
• Promoted tendon healing markers

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon anastomosis and counteracts cuprizone brain injuries and motor disability, published in Journal of Physiology and Pharmacology (Sikiric P et al., 2013; PMID: 24304574):

Investigated BPC-157's effects on intestinal healing and neurological outcomes in animal models.

• Improved colitis healing
• Enhanced anastomosis healing
• Reduced neurological damage markers

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin, published in Blood Coagulation & Fibrinolysis (Stupnisek M et al., 2015; PMID: 25897838):

Examined effects on bleeding and coagulation in anticoagulated rats.

• Reduced bleeding time
• Improved platelet function
• Potential hemostatic effects

Related Reading#

• BPC-157 research studies and evidence
• BPC-157 dosing protocols
• BPC-157 side effects profile
• Alprostadil research guide
• ARA-290 research guide